Exercise program for lymphoma patients undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of a tailored exercise program for adults diagnosed with lymphoma who are receiving immunochemotherapy. The intervention aims to enhance cardiorespiratory fitness, strength, psychological well-being, and overall quality of life while reducing fatigue and frailty. The research focuses on a homogeneous group of lymphoma patients, particularly those aged 70 and older, and seeks to provide scientific evidence in a field that has been minimally studied. Additionally, the study will analyze the effects of exercise from a gender perspective, addressing baseline differences and outcomes post-intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: ≥18 years old.
* Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy.
* Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions.
* Have a mobile phone to be able to contact the person and download the physical activity level app.
* Eastern Cooperative Oncology Group performance status (ECOG) ≤2.
* Life expectancy \>12 months.
* Availability and desire to participate throughout the study period.

Exclusion Criteria:

* Have a contraindication to moderate-high intensity exercise.
* Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise.
* Have plans to be outside city more than two weeks.
* People who are already physically active (that comply with the recommendations of WHO: \> 150 minutes of exercise moderate/weekly, plus training force two days/week).
* Treatment based only with immunotherapy.
* Central nervous system involvement due to lymphoma.
* Have any important history that limit the capacity of the patient to participate in the study.

Where it's running

• Hospital Universitario Donostia (HUD)
  San Sebastián, Guipuzcoa, Spain Recruiting
• Hospital Universitario Araba (HUA)
  Vitoria - Gateiz, Araba, Spain Not yet recruiting
• Hospital Universitario Galdakao (HUG)
  Galdakao, Bizkaia, Spain Active not recruiting

Study contacts

• Principal investigator: Izaskun Zeberio Etxetxipia — Hospital Donostia
• Study coordinator: Clinical Research Platform - Health Research Institut Biogipuzkoa
• Email: OSID.INVESTCLINICA@osakidetza.eus
• Phone: +34943006140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.